glp-1 supply shortage news november 2025 FDA restricts non-approved compounded weight loss products GLP-1 Agonists Market Report 2025-2033,

We review the historical context of PA and its digitization, describe the technical ePA workflow and standards, and analyze current practice patterns and data

Conclusion The GLP-1 receptor agonist market is poised for substantial growth over the forecast period, driven by the increasing prevalence of type 2 diabetes, obesity, and other metabolic disorders globally

See our guide on where to buy peptides in 2026 for sourcing considerations

And its a risky intervention

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure

For older adults or those with significant comorbidities, a slightly higher target of below 8 percent may be appropriate, as aggressive glucose lowering in these populations can increase the risk of hypoglycemia, which carries its own serious consequences